5 completed, 2 active not recruiting, 1 terminated. 6 Phase 2, 2 Phase 1, 1 Early Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 6 | Completed 4, Active not recruiting 2 |
| Phase 1 | 2 | Completed 2 |
| Early Phase 1 | 1 | Terminated 1 |
Follow Recurrent Gastric Carcinoma: new trials by email Literature Review of Recurrent Gastric Carcinoma trials Research Report on Recurrent Gastric Carcinoma
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Measuring the Effects of Talazoparib in Patients With Advanced Cancer and DNA Repair Variations Biopsy Procedure, Biospecimen Collection, Computed Tomography - Anatomic Stage III Breast Cancer AJCC v8, Anatomic Stage IV Breast Cancer AJCC v8 | Phase 2 | Active not recruiting | National Cancer Institute (NCI) | 29 | 2021-04-26 | 2026-11-18 |
| Heated Intra-peritoneal Chemotherapy With Doxorubicin and Cisplatin for Abdominal for Pelvic Tumors in Pediatric Patients Cisplatin, Cytoreductive Surgery, Doxorubicin - Malignant Abdominal Neoplasm, Malignant Pelvic Neoplasm | Early Phase 1 | Terminated | Mayo Clinic | 2 | 2019-11-08 | 2025-02-20 |
| Olaparib and Ramucirumab in Treating Patients With Metastatic or Locally Recurrent Gastric or Gastroesophageal Junction Cancer That Cannot Be Removed by Surgery Olaparib, Ramucirumab - Metastatic Esophageal Carcinoma, Metastatic Gastric Carcinoma | Phase 1 / Phase 2 | Completed | National Cancer Institute (NCI) | 51 | 2018-02-06 | 2026-02-03 |
| Epacadostat and Pembrolizumab in Treating Patients With Metastatic or Unresectable Gastroesophageal Junction or Gastric Cancer Epacadostat, Pembrolizumab - Gastric Adenocarcinoma, Gastroesophageal Junction Adenocarcinoma | Phase 2 | Completed | George Albert Fisher | 3 | 2017-09-13 | 2024-01-23 |
| Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial) Adavosertib, Afatinib, Afatinib Dimaleate - Advanced Lymphoma, Advanced Malignant Solid Neoplasm | Phase 2 | Active not recruiting | National Cancer Institute (NCI) | 6452 | 2015-08-17 | 2026-11-12 |
| Vaccine Therapy With or Without Sirolimus in Treating Patients With NY-ESO-1 Expressing Solid Tumors DEC-205/NY-ESO-1 Fusion Protein CDX-1401, Laboratory Biomarker Analysis, Pharmacological Study - Anaplastic Astrocytoma, Anaplastic Oligoastrocytoma | Phase 1 | Completed | Roswell Park Cancer Institute | 18 | 2012-03-01 | 2016-10-04 |
| Akt Inhibitor MK2206 in Treating Patients With Advanced Gastric or Gastroesophageal Junction Cancer Akt Inhibitor MK2206 - Adenocarcinoma of the Gastroesophageal Junction, Diffuse Gastric Adenocarcinoma | Phase 2 | Completed | National Cancer Institute (NCI) | 75 | 2011-01-01 | 2016-01-18 |
| Pralatrexate and Oxaliplatin in Treating Patients With Unresectable or Metastatic Esophageal, Stomach, or Gastroesophageal Junction Cancer Laboratory Biomarker Analysis, Oxaliplatin, Pralatrexate - Adenocarcinoma of the Gastroesophageal Junction, Esophageal Undifferentiated Carcinoma | Phase 2 | Completed | Roswell Park Cancer Institute | 35 | 2010-09-01 | 2017-12-13 |
Stomach Neoplasms (8) · Esophageal Neoplasms (4) · Ovarian Neoplasms (4) · Breast Neoplasms (3) · Prostatic Neoplasms (3) · Carcinoma, Hepatocellular (2) · Carcinoma, Renal Cell (2) · Colonic Neoplasms (2) · Colorectal Neoplasms (2) · Lung Neoplasms (2) · Melanoma (2) · Pancreatic Neoplasms (2) · Rectal Neoplasms (2) · Sarcoma (2) · Urinary Bladder Neoplasms (2)
Digestive System Diseases (8) · Digestive System Neoplasms (8) · Gastrointestinal Diseases (8) · Gastrointestinal Neoplasms (8) · Neoplasms (8) · Neoplasms by Site (8) · Stomach Diseases (8) · Esophageal Diseases (5) · Head and Neck Neoplasms (5) · Adnexal Diseases (4) · Endocrine Gland Neoplasms (4) · Endocrine System Diseases (4) · Female Urogenital Diseases (4) · Female Urogenital Diseases and Pregnancy Complications (4) · Genital Diseases (4)
Magnetic Resonance Spectroscopy (3) · Specimen Handling (3) · Biopsy (2) · X-Rays (2) · 1,2-diaminocyclohexaneplatinum II citrate (1) · 10-propargyl-10-deazaaminopterin (1) · 2-(3-(2-(1-isopropyl-3-methyl-1H-1,2-4-triazol-5-yl)-5,6-dihydrobenzo(f)imidazo(1,2-d)(1,4)oxazepin-9-yl)-1H-pyrazol-1-yl)-2-methylpropanamide (1) · 2C4 antibody (1) · AZD4547 (1) · Ado-Trastuzumab Emtansine (1) · Afatinib (1) · CT-P6 (1) · Cisplatin (1) · Crizotinib (1) · Cytoreduction Surgical Procedures (1)
National Cancer Institute (NCI) (4) · Roswell Park Cancer Institute (2) · George Albert Fisher (1) · Mayo Clinic (1)
United States (8) · Canada (1) · Guam (1) · Puerto Rico (1)
A P Chen (1) · George A Fisher, MD (1) · Keith T Flaherty (1) · Kunle Odunsi (1) · Michael Cecchini (1) · Nikhil Khushalani (1) · Patricio C. Gargollo, M.D. (1) · Ramesh Ramanathan (1)
PMID 25827820, PMID 26586415, PMID 32463741, PMID 33048619, PMID 35133871, PMID 35138919, PMID 36351402, PMID 37053535, PMID 37322121, PMID 37934000, PMID 38591867, PMID 39666929, PMID 39693587, PMID 39913886, PMID 40132910, PMID 40865033, PMID 41066729
P30CA016056 (2), R01CA158318 (1), U10CA032102 (1), U10CA180820 (1), U10CA180888 (1), U24CA196172 (1), UM1CA186689 (1)